Atopic dermatitis

Cover Page

Cite item

Full Text

Abstract

Atopic dermatitis is one of the most common diseases (20‒40% among skin diseases) that occur in both genders worldwide and in different age groups. The problem urgency is caused by an increase in morbidity, a chronic relapsing course that often leads to a decrease in the quality of life and disability, low efficiency of traditional treatment methods, and limited access to contemporary effective targeted therapy. The clinical guidelines, which aimed to optimize care for patients with atopic dermatitis, contain up-to-date information on epidemiology, etiological factors, mechanisms of development and pathogenesis, aspects of the clinical presentation and disease course, current diagnostic methods (including allergological examination methods), as well as approaches to treatment (including traditional methods and modern targeted therapy). The indications for allergen-specific immunotherapy are determined, and the aspects of its implementation are described. The procedure for the provision of medical care, prevention, and follow-up monitoring is outlined. Clinical practice guidelines for atopic dermatitis are intended for practitioners of all specialties, students, teachers of medical schools, residents, graduate students, and researchers.

About the authors

Alexey A. Kubanov

State Research Center of Dermatovenerology and Cosmetology

Email: alex@cnikvi.ru
ORCID iD: 0000-0002-7625-0503
SPIN-code: 8771-4990

MD, Dr. Sci. (Med.), Senior Research Associate

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

Leyla S. Namazova-Baranova

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; Pirogov Russian National Research Medical University

Email: leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531
SPIN-code: 1312-2147

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Rakhim M. Khaitov

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: rm.khaitov@nrcii.ru
ORCID iD: 0000-0003-1829-0424

MD, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Natalya I. Ilyina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Anna A. Alekseeva

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: aleksaa06@yandex.ru
ORCID iD: 0000-0002-8023-2543
SPIN-code: 7253-7970

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Eduard T. Ambarchian

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; State Autonomous Institution “National Medical Research Center of Children’s Health”

Email: edo_amb@mail.ru
ORCID iD: 0000-0002-8232-8936
SPIN-code: 4878-5562

MD, Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Sofya I. Artemyeva

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: sofya.chern@gmail.com
ORCID iD: 0000-0002-2793-8862
SPIN-code: 2627-9842
Russian Federation, Moscow

Mark I. Arshinskiy

Regional Skin and Venereological Dispensary

Email: kkvd80@inbox.ru
ORCID iD: 0000-0003-2952-9082
SPIN-code: 1821-9471
Russian Federation, Khabarovsk

Natalia G. Astafyeva

Saratov State Medical University named after V.I. Razumovsky

Email: astang@mail.ru
ORCID iD: 0000-0002-7691-4584
SPIN-code: 9941-7013

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saratov

Elena A. Vishneva

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562
SPIN-code: 1109-2810

MD, Dr. Sci. (Med)

Russian Federation, Moscow

Vladimir A. Volnukhin

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: vvoln@rambler.ru
ORCID iD: 0000-0002-8363-5188
SPIN-code: 8206-2731

MD, Dr. Sci (Med), Professor

Russian Federation, Moscow

Inna V. Danilycheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Olga G. Elisyutina

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci. (Med.), Senior Research Associate

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Roman V. Epishev

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; State Autonomous Institution “National Medical Research Center of Children’s Health”

Email: drepishev@gmail.com
ORCID iD: 0000-0002-4107-4642
SPIN-code: 5162-7846

MD, Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Aleksandr V. Zhestkov

Samara State Medical University

Email: avzhestkov2015@yandex.ru
ORCID iD: 0000-0002-3960-830X
SPIN-code: 2765-9617

MD, Dr. Sci. (Med.), Professor

Russian Federation, Samara

Maryana B. Zhilova

State Research Center of Dermatovenerology and Cosmetology

Email: zhilova@cnikvi.ru
ORCID iD: 0000-0003-2545-2129
SPIN-code: 8930-4073

MD, Dr. Sci. (Med.)

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

Olga V. Zhukova

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: klinderma@inbox.ru
ORCID iD: 0000-0001-5723-6573
SPIN-code: 8584-7564

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Denis V. Zaslavsky

Saint Petersburg State Pediatric Medical University

Email: venerology@gmail.com
ORCID iD: 0000-0001-5936-6232
SPIN-code: 5832-9510

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Lyudmila F. Znamenskaya

State Research Center of Dermatovenerology and Cosmetology

Email: znaml@cnikvi.ru
ORCID iD: 0000-0002-2553-0484
SPIN-code: 9552-7850

MD, Dr. Sci. (Med.)

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

Arfenya E. Karamova

State Research Center of Dermatovenerology and Cosmetology

Email: karamova@cnikvi.ru
ORCID iD: 0000-0003-3805-8489
SPIN-code: 3604-6491

MD, Cand. Sci. (Med.)

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

Nikolay G. Korotky

Pirogov Russian National Research Medical University

Email: kng40@mail.ru
ORCID iD: 0000-0002-0913-000X
SPIN-code: 7319-7942

MD, Dr. Sci (Med.), Professor

Russian Federation, Moscow

Muza M. Kokhan

Ural Research Institute of Dermatovenereology and Immunopathology

Email: mkokhan@yandex.ru
ORCID iD: 0000-0001-6353-6644
SPIN-code: 3470-9306

MD, Dr. Sci (Med.), Professor

Russian Federation, Ekaterinburg

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Nikolay V. Kungurov

Ural Research Institute of Dermatovenereology and Immunopathology

Email: N.kungurov@gmail.com
ORCID iD: 0000-0002-4134-047X
SPIN-code: 3903-2425

MD, Dr. Sci. (Med.), Professor

Russian Federation, Ekaterinburg

Julia G. Levina

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: julia.levina@mail.ru
ORCID iD: 0000-0002-2460-7718
SPIN-code: 4626-2800

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Andrey N. Lvov

Central State Medical Academy of Department of Presidential Affairs; Lomonosov Moscow State University

Email: alvov@mail.ru
ORCID iD: 0000-0002-3875-4030
SPIN-code: 1053-3290

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow; Moscow

Alexander I. Materikin

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; State Autonomous Institution “National Medical Research Center of Children’s Health”

Email: al_m86@bk.ru
ORCID iD: 0000-0002-6034-8231
SPIN-code: 5935-8090

MD, Cand. Sci. (Med.)

Russian Federation, Moscow; Moscow

Olesya S. Mishina

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: olesya.mishina@mail.ru
ORCID iD: 0000-0002-6415-4338

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Konstantin N. Monakhov

Pavlov First Saint Petersburg State Medical University

Email: knmonakhov@gmail.com
ORCID iD: 0000-0002-8211-1665
SPIN-code: 1837-2098

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Nikolay N. Murashkin

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences; State Autonomous Institution “National Medical Research Center of Children’s Health”

Email: m_nn2001@mail.ru
ORCID iD: 0000-0003-2252-8570
SPIN-code: 5906-9724

MD, Dr. Sci. (Med.)

Russian Federation, Moscow; Moscow

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Alexander N. Pampura

Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University

Email: apampura1@mail.ru
ORCID iD: 0000-0001-5039-8473
SPIN-code: 9722-7961

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Xenia I. Plakhova

State Research Center of Dermatovenerology and Cosmetology

Email: plahova@cnikvi.ru
ORCID iD: 0000-0003-4169-4128
SPIN-code: 7634-5521

MD, Dr. Sci. (Med.)

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

Nikolay N. Potekaev

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: klinderma@mail.ru
ORCID iD: 0000-0002-9578-5490
SPIN-code: 8862-5688

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Olga A. Prytulо

S.I. Georgievsky Medical Academy of the Crimean Federal University named after V.I. Vernadsky

Email: 55550256@mail.ru
ORCID iD: 0000-0001-6515-1924
SPIN-code: 2988-8463

MD, Dr. Sci. (Med.), Professor

Russian Federation, Simferopol

Konstantin I. Raznatovskiy

North-Western State Medical University named after I.I. Mechnikov

Email: konstantan.r@bk.ru
ORCID iD: 0000-0003-1022-7463
SPIN-code: 4587-2393

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

Svetlana G. Sapuntsova

The Far-Eastern State Medical University

Email: ssfesmu@yandex.ru
ORCID iD: 0000-0001-9231-2391
SPIN-code: 1875-7155

MD, Cand. Sci. (Med.), Associate Professor

Russian Federation, Khabarovsk

Liliia R. Selimzianova

Research Institute of Pediatrics and Children’s Health of Central Clinical Hospital of the Russian Academy of Sciences

Email: lilysir@mail.ru
ORCID iD: 0000-0002-3678-7939
SPIN-code: 5508-1689

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Olesya V. Skorokhodkina

Kazan State Medical University

Email: olesya-27@rambler.ru
ORCID iD: 0000-0001-5793-5753
SPIN-code: 8649-6138

MD, Dr. Sci. (Med.), Professor

Russian Federation, Kazan

Elena S. Fedenko

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Daria S. Fomina

Сlinical State Hospital No. 52; First Sechenov Moscow State Medical University (Sechenov University)

Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538

MD, Associate Professor

Russian Federation, Moscow; Moscow

Nataliya V. Frigo

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Healthcare Department

Email: frigo2013@yandex.ru
ORCID iD: 0000-0001-6231-971X
SPIN-code: 7009-9991

MD, Dr. Sci. (Med)

Russian Federation, Moscow

Zoya V. Frolova

Regional Skin and Venereological Dispensary

Email: kkvd80@inbox.ru
ORCID iD: 0000-0002-2633-1452
SPIN-code: 9490-7107
Russian Federation, Khabarovsk

Musa R. Khaitov

Pirogov Russian National Research Medical University; National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: mr.khaitov@nrcii.ru
ORCID iD: 0000-0003-4961-9640
SPIN-code: 3199-9803

MD, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences

Russian Federation, Moscow; 24, Kashirskoyw shosse, Moscow, 115522

Vadim V. Chikin

State Research Center of Dermatovenerology and Cosmetology

Author for correspondence.
Email: chikin@cnikvi.ru
ORCID iD: 0000-0002-9688-2727
SPIN-code: 3385-4723

MD, Dr. Sci. (Med.)

Russian Federation, 3, b. 6, Korolenko str., Moscow, 107076

References

  1. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi: 10.1038/ng1767
  2. McGirt LY, Beck LA. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):202–208. doi: 10.1016/j.jaci.2006.04.033
  3. Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi: 10.4161/jkst.24137
  4. Gandhi NA, Pirozzi G, Graham N.M. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443
  5. Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi: 10.1016/j.jaci.2016.06.010
  6. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891
  7. Kubanov AA, Bogdanova EV. Organization and results of medical care in the profile of dermatovenerology in the Russian Federation. The results of 2018. Bulletin of Dermatology and Venereology. 2019;95(4):8–23. (In Russ). doi: 10.25208/0042-4609-2019-95-4-8-23
  8. Schneider L, Hanifin J, Boguniewicz M, et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388–398. doi: 10.1111/pde.12867
  9. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475–1482. doi: 10.1111/all.12049
  10. Van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007;120(3):565–569. doi: 10.1016/j.jaci.2007.05.042
  11. Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78(1):54–61.e1. doi: 10.1016/j.jaad.2017.08.002
  12. Illi S, von Mutius E, Lau S, et al. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol. 2001;108(5):709–714. doi: 10.1067/mai.2001.118786
  13. Aw M, Penn J, Gauvreau GM, et al. Atopic march: collegium internationale allergologicum update 2020. Int Arch Allergy Immunol. 2020;181(1):1–10. doi: 10.1159/000502958
  14. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin N Am. 2010;30(3):269–280. doi: 10.1016/j.iac.2010.06.003
  15. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi: 10.1016/j.anai.2017.10.037
  16. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):209–213. doi: 10.1016/j.jaci.2006.04.043
  17. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–931. doi: 10.1016/j.jaci.2004.01.778
  18. Atopic dermatitis: recommendations for practitioners. The Russian conciliatory national document on atopic dermatitis. Ed. by P.M. Khaitov, A.A. Kubanov. Moscow: Pharmacus Print; 2002. 192 p. (In Russ).
  19. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44–47. doi: 10.2340/00015555924447
  20. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi: 10.1016/j.jaad.2013.10.010
  21. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949–972. doi: 10.1016/j.jaad.2010.02.062
  22. Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116(2):377–383. doi: 10.1016/j.jaci.2005.05.017
  23. Clinical dermatovenerology. Vol. II. Ed. by Yu.K. Skripkin, Yu.S. Butov. Moscow: GEOTAR-Media; 2009. 928 p.
  24. Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294. doi: 10.1016/j.jaad.2015.09.062
  25. Oranje AP, Stalder JF, Taieb A, et al. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997;8(1):28–34. doi: 10.1111/j.1399-3038.1997.tb00139.x
  26. Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.x
  27. Giam Y.C., Hebert A.A., Dizon M.V. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016;6(2):120–128. doi: 10.5415/apallergy.2016.6.2.120
  28. Breternitz M, Kowatzki D, Langenauer M, et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39–45. doi: 10.1159/000111134
  29. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008;19(6):308–315.
  30. Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011;10(7):744–749.
  31. Lindh JD, Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015;16(5):341–359. doi: 10.1007/s40257-015-0146-4
  32. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531–537.
  33. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61–67. doi: 10.1159/000096915
  34. Msika P, De Belilovsky C, Piccardi N, et al. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008;25(6):606–612. doi: 10.1111/j.1525-1470.2008.00783.x
  35. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997;14(4):321–324. doi: 10.1111/j.1525-1470.1997.tb00968.x
  36. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008;22(1):73–82. doi: 10.1111/j.1468-3083.2007.02351.x
  37. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106–1111.
  38. Leung TN, Chow CM, Chow MP, et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr (new series). 2013;18(2):96–104.
  39. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24(3):317–328. doi: 10.1111/j.1468-3083.2009.03415.x
  40. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009;26(3):273–278. doi: 10.1111/j.1525-1470.2009.00911.x
  41. Guidance on Prescribing. In: British National Formulary No.60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010.
  42. Dabade TS, Davis DM, Wetter DA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012;67(1):100–106. doi: 10.1016/j.jaad.2011.06.025
  43. Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154(4):579–585. doi: 10.1111/j.1365-2133.2006.07157.x
  44. Devillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using ‘wet-wrap’ dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology. 2002;204(1):50–55. doi: 10.1159/000051810
  45. Goodyear HM, Spowart K, Harper JI. ‘Wet-wrap’ dressings for the treatment of atopic eczema in children. Br J Dermatol. 1991;125(6):604. doi: 10.1111/j.1365-2133.1991.tb14807.x
  46. Brenninkmeijer EE, Spuls PI, Lindeboom R, et al. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010;163(4):823–831. doi: 10.1111/j.1365-2133.2010.09858.x
  47. Pels R, Sterry W, Lademann J. Clobetasol propionate ― where, when, why? Drugs Today (Barc). 2008;44(7):547–557. doi: 10.1358/dot.2008.44.7.1122221
  48. Breneman D, Fleischer AB, Kaplan D, et al. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005;4(3):330–336.
  49. Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154–171. doi: 10.1016/j.curtheres.2005.06.010
  50. Datz B, Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J Am Acad Dermatol. 1991;25(6 Pt 2):1157–1160. doi: 10.1016/0190-9622(91)70316-t
  51. Viglioglia P, Jones ML, Peets EA. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res. 1990;18(6):460–467. doi: 10.1177/030006059001800603
  52. Vanderploeg DE. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976;69(7):862–863. doi: 10.1097/00007611-197607000-00017
  53. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984;1(3):246–253.
  54. Cabrera ME. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream. J Int Med Res. 1984;12(3):163–169. doi: 10.1177/030006058401200305
  55. Lodolo JC. Diprolene cream in the treatment of severe or resistant corticosteroid-responsive dermatoses. J Int Med Res. 1984;12(2):114–120. doi: 10.1177/030006058401200209
  56. Peterkin GA, Morley WN, Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema. Br Med J. 1962;1(5289):1392. doi: 10.1136/bmj.1.5289.1392
  57. Hanifin JM. Atopic dermatitis. Special clinical complications. Postgrad Med. 1983;74(3):188–199. doi: 10.1080/00325481.1983.11698425
  58. Cadmus SD, Sebastian KR, Warren D, et al. Efficacy and patient opinion of wet‐wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split‐body control study. Pediatr Dermatol. 2019;36(4):437–441.
  59. Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998;39(2 Pt 1):226–231. doi: 10.1016/s0190-9622(98)70080-5
  60. Bleehen SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995;133(4):592–597. doi: 10.1111/j.1365-2133.1995.tb02711.x
  61. Belousova TA, Goryachkina MV. Experience of using fluticasone propionate (Kutivate) in the treatment of psoriasis, eczema and atopic dermatitis. Effective Pharmacotherapy. 2010;(9):24–29. (In Russ).
  62. Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55(1):145–163. doi: 10.2165/00003495-199855010-00009
  63. Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol. 1991;24(4):603–607. doi: 10.1016/0190-9622(91)70092-g
  64. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol. 1999;38(8):604–606. doi: 10.1046/j.1365-4362.1999.00759.x
  65. Tomilova AYu, Torshkhoeva RM, Gevorkyan AK, Voznesenskaya NI. Efficacy and safety of mometasone furoate in atopic dermatitis in children. Pediatric Pharmacology. 2009;6(4):123–127. (In Russ).
  66. Shaipov TS, Mazitova LP. The use of mometasone furoate in the treatment of atopic dermatitis in children. Pediatric Pharmacology. 2007;4(5):41–44. (In Russ).
  67. Nenasheva NM. Features of atopic dermatitis in adult patients Effective pharmacotherapy. Dermatovenerology and Dermatocosmetology. 2012;(3):6–15. (In Russ).
  68. Lane AT. Efficacy and safety of topical steroids in paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 1997;8:S24–S27.
  69. Faergemann J, Christensen O, Sjövall P, et al. An open study of efficacy and safety of long‐term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000;14(5):393–396.
  70. Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J Dermatol Treatm. 2009;3(Suppl. 2):13–15. doi: 10.3109/09546639209092767
  71. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25(3):251–258. doi: 10.1111/j.1468-3083.2010.03789.x
  72. Bieber T, Vick K, Fölster-Holst R, et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007;62(2):184–189. doi: 10.1111/j.1398-9995.2006.01269.x
  73. Kondratieva YuS, Karkhova VV. Experience of using 0.1% methylprednisolone aceponate in the complex therapy of steroid-sensitive dermatoses. Bulletin of Dermatology and Venereology. 2016;(1):93–98. (In Russ).
  74. Chikin VV. Methylprednisolone aceponate and dexpanthenol in topical therapy of patients with AtD. Bulletin of Dermatology and Venereology. 2014;90(5):112–116. (In Russ). doi: 10.25208/0042-4609-2014-90-5-112-116
  75. Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol. 1984;23(8):565–566. doi: 10.1111/j.1365-4362.1984.tb04214.x
  76. Panja SK, Gangopadhaya AK, Sharma SD. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses. Indian J Dermatol. 1988;33(1):1–4.
  77. Makarova IV, Gaiduk IM, Zhiglinskaya OV, et al. The use of 0.05% cream of alclomethasone dipropionate in the treatment of atopic dermatitis in young children. Questions of Modern Pediatrics. 2004;3(4):84–87. (In Russ).
  78. Korotky NG, Tikhomirov AA, Gamayunov BN. Evaluation of the clinical efficacy of the modern steroid alclomethasone dipropionate (Afloderm) in the external therapy of atopic dermatitis in children. Clinical Dermatology and Venereology. 2007;(6):24–31. (In Russ).
  79. Toropova NP, Cherkasova LA, Platonova IN, et al. Experience of using the drug “Afloderm” (alclomethasone dipropionate) in pediatric dermatological practice. Russian Journal of Skin and Venereal Diseases. 2003;(3):39–40. (In Russ).
  80. Veien NK, Hattel T, Justesen O, et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res. 1984;12(5):310–313. doi: 10.1177/030006058401200509
  81. Rajka G, Verjans HL. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res. 1986;14(2):85–90. doi: 10.1177/030006058601400206
  82. Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed. 2010;8(2):72–79.
  83. Koopmans B, Lasthein Andersen B, Mork NJ, et al. Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat. 1995;6(2):103–106. doi: 10.3109/09546639509097161
  84. Saki N, Jowkar F, Alyaseen S, et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. J Dermatolog Treat. 2013;24(6):447–449. doi: 10.3109/09546634.2013.782384
  85. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109(3):547–555. doi: 10.1067/mai.2002.121832
  86. Matheson R, Kempers S, Breneman D, et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008;7(3):266–271.
  87. Sears HW, Bailer JW, Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997;19(4):710–719.
  88. Ignatiev DV, Kochergin NG. Local corticosteroids in the practice of a dermatologist. Features of hydrocortisone butyrate (locoid). Dermatology. Appendix Journal Consilium Medicum. 2007;(1):50–54. (In Russ).
  89. Udompataikul M, Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366–374.
  90. Udompataikul M, Srisatwaja W. Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study. J Eur Acad Dermatol Venereol. 2011;25(6):660–665.
  91. Sergeev YuV, Ivanov OL, Novikov DK, et al. Atopic dermatitis: modern diagnosis and treatment. Immunopathology, Allergology, Infectology. 2001;(4):39–63. (In Russ).
  92. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330(7490):516.
  93. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997;337(12):816–821. doi: 10.1056/NEJM199709183371203
  94. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000;136(8):999–1006. doi: 10.1001/archderm.136.8.999
  95. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144–156. doi: 10.3109/09546630903401470
  96. Bornhövd EC, Burgdorf WH, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3(5):708–712.
  97. Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt. 2003;54(5):432–439.
  98. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152(6):1282–1289. doi: 10.1111/j.1365-2133.2005.06592.x
  99. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003;139(9):1184–1186. doi: 10.1001/archderm.139.9.1184
  100. Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of secondary prophylactic treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008;159(6):1322–1330. doi: 10.1111/j.1365-2133.2008.08807.x
  101. Healy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol. 2011;164(2):387–395. doi: 10.1111/j.1365-2133.2010.10141.x
  102. Reitamo S, Mandelin J, Rubins A, et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009;48(4):348–355. doi: 10.1111/j.1365-4632.2009.03853.x
  103. Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159(4):942–951. doi: 10.1111/j.1365-2133.2008.08747.x Ruzicka
  104. Mandelin JM, Remitz A, Virtanen HM, et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010;21(3):167–170. doi: 10.3109/09546630903493329
  105. Mandelin J, Remitz A, Virtanen HM, et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010;90(2):170–174. doi: 10.2340/00015555-0803
  106. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102(4 Pt 1):637–644. doi: 10.1016/s0091-6749(98)70281-7
  107. Elisyutina OG, Fedenko ES, Shtyrbul OV, Niyazov DD. The use of tacrolimus in patients with moderate and severe atopic dermatitis. The first clinical experience in Russia. Russian Journal of Allergy. 2011;(6):68–76. (In Russ).
  108. Proshutinskaya DV, Butareva MM, Inoyatova LA. New possibilities of therapy of atopic dermatitis in children and adults. Bulletin of Dermatology and Venereology. 2013;(3):78–82. (In Russ).
  109. Samtsov AV, Sukharev AV, Patrushev AV, Bondar OI. Clinical efficacy, safety and tolerability of 0.1% tacrolimus ointment in the treatment of moderate and severe atopic dermatitis. Bulletin of Dermatology and Venereology. 2012;(2):71–77. (In Russ).
  110. Samtsov AV, Sukharev AV, Patrushev AV. Treatment of atopic dermatitis: advantages of tacrolimus over topical corticosteroids. Effective Pharmacotherapy. 2014;(19):4–10. (In Russ).
  111. Van Leent EJ, Graber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134(7):805–809. doi: 10.1001/archderm.134.7.805
  112. Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205(3):271–277. doi: 10.1159/000065863
  113. Wahn U, Bos J, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: 10.1542/peds.110.1.e2
  114. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003;142(2):155–162. doi: 10.1067/mpd.2003.65
  115. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46(4):495–504. doi: 10.1067/mjd.2002.122187
  116. Langley RG, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol. 2008;25(3):301–307. doi: 10.1111/j.1525-1470.2008.00671.x
  117. Luger T, van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144(4):788–794. doi: 10.1046/j.1365-2133.2001.04134.x
  118. Eichenfield LF, Thaci D, de Prost Y, et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology. 2007;11(Suppl 1):3–17. doi: 10.1159/000102116
  119. Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366–373. doi: 10.1080/09546634.2018.1524823
  120. Kubanov AA, Petrovsky FI. Activated zinc pyrithione (Skin cap). Mechanisms of action. Clinical application. Bulletin of Dermatology and Venereology. 2009;(5):35–42. (In Russ).
  121. Fassakhov RS, Pampura AN, Korostovtsev DS, et al. Skin-Cap in the treatment of atopic dermatitis in children (according to the results of the Russian multicenter study KADET). Russian Journal of Allergy. 2007;(2):75–81. (In Russ).
  122. Fassakhov RS, Pampura AN, Korostovtsev DS, et al. Efficacy and safety of activated zinc pyrithione (skin cap) in the treatment of atopic dermatitis in children (results of a Russian multicenter study). Bulletin of Pediatric Pharmacology and Nutriciology. 2006;3(6):28–31. (In Russ).
  123. Neurodermatoses. In: Skin and venereal diseases: A guide for doctors. In two volumes. 2nd ed., reprint. and additional vol. 2. Ed. by Yu.K. Skripkin, V.N. Mordovtsev. Moscow: Meditsina; 1999. Р. 9–49. (In Russ).
  124. Yoshida H, Niimura M, Ueda H, et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy. 1989;62(6):507–512.
  125. Grigorieva I, Sergeev A, Manina I, Kudryavtseva E. Immunopathology and biochemical bases of atopic states. Doctor. 2012;(4):86–91. (In Russ).
  126. Morozova SV, Luss LV. Chloropyramine: modern aspects of application. Current Pediatrics. 2007;6:(1):137–140. (In Russ).
  127. Goryachkina MV, Belousova TA. Chloropyramine: clinical aspects of application. Russian Medical Journal. Medical Review. 2014;22(24):1785–1789. (In Russ).
  128. Petrova KS, Petrova GA. Chloropyramine (suprastin) ― modern aspects of the use in the treatment of allergodermatoses. Russian Medical Journal. 2014;22(8):617–620. (In Russ).
  129. Revyakina VA. Antihistamines in clinical practice. Russian Medical Journal. 2014;22(11):854–856. (In Russ).
  130. Behrendt H, Ring J. Histamine, antihistamines and atopic eczema. Clin Exp Allergy. 1990;20(Suppl 4):25–30. doi: 10.1111/j.1365-2222.1990.tb02473.x
  131. Langeland T, Fagertun HE, Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994;49(1):22–26. doi: 10.1111/j.1398-9995.1994.tb00768.x
  132. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992;14(1):17–21.
  133. Popova IS, Matushevskaya EV, Svirshchevskaya EV. Double-blind placebo-controlled study of the efficacy and tolerability of clarotadine in atopic dermatitis. RMJ. 2001;9(4):477–483. (In Russ).
  134. Hannuksela M, Kalimo K, Lammintausta K, et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993;70(2):127–133.
  135. La Rosa M, Ranno C, Musarra I, et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy. 1994;73(2):117–122.
  136. Pavlova OV. Experience of using cetirizine (allertek) in the treatment of patients with atopic dermatitis and eczema. Bulletin of Dermatology and Venereology. 2005;(4):41–43. (In Russ).
  137. Makarova IV, Zhiglinskaya OV, Mikhailova EA, Sukhorukova VG. Comparative efficacy of generic cetirizine (Egis production, Hungary) and original in the form of drops in the complex therapy of atopic dermatitis in young children. Current Pediatrics. 2007;6(3):85–88. (In Russ).
  138. Samsygina GA. Allergic diseases in children. Moscow: GEOTAR-Media; 2019. 272 p. (In Russ).
  139. Delyagin VM, Urazbagambetov A. The use of Suprastinex (levocetirizine) in atopy in children and adolescents. Russian Medical Journal. 2012;20(16):828–830. (In Russ).
  140. Elisyutina OG, Fedenko ES, Fedoskova TG, Luss LV. Efficacy of levocetirizine therapy in patients with allergodermatoses. Russian Journal of Allergy. 2012;(5):69–75. (In Russ).
  141. Tamrazova OB. Pathogenetic therapy of children suffering from severe forms of atopic dermatitis. Russian Medical Journal. 2013;(2):108–114. (In Russ).
  142. Nazhmutdinova DK, Shvets OI. Levocetirizine: reboot. Russian Medical Journal. 2011;19(21):1324–1326. (In Russ).
  143. Kamaev AV, Trusova OV, Kamaeva IA. Itching in atopic dermatitis in children: known mechanisms and possibilities of its long-term control. Russian Medical Journal. 2015;23(3):142–146. (In Russ).
  144. Monakhov SA, Korzhachkina NB, Olisova OYu. Narrow-wave phototherapy 311 nm in the treatment of patients with atopic dermatitis. Russian Journal of Skin and Venereal Diseases. 2012;(3):25–27. (In Russ).
  145. Majoie IM, Oldhoff JM, van Weelden H, et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2009;60(1):77–84. doi: 10.1016/j.jaad.2008.08.048
  146. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001;357(9273):2012–2016. doi: 10.1016/S0140-6736(00)05114-X
  147. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28–33.
  148. Seccombe L, Wynne MD, Clancy C, et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021;37(1):34–38.
  149. Gambichler T, Othlinghaus N, Tomi NS, et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol. 2009;160(3):652–658. doi: 10.1111/j.1365-2133.2008.08984.x
  150. Bogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016;55(7):e380–385. doi: 10.1111/ijd.13213
  151. Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001;45:503–507.
  152. Malinowska K, Wozniacka A, Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020;37(6):962–967.
  153. Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000;42 (2 Pt 1):254–257.
  154. Pugashetti R, Lim HW, Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J Dermatolog Treat. 2010;21(6):326–330. doi: 10.3109/09546630903341986
  155. Tzaneva S, Kittler H, Holzer G, et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010;162(3):655–660. doi: 10.1111/j.1365-2133.2009.09514.x
  156. Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014;170(3):501–513. doi: 10.1111/bjd.12645
  157. Pérez-Ferriols A, Aranegui B, Pujol-Montcusí JA, et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015;106(5):387–401. doi: 10.1016/j.ad.2014.12.017
  158. Uetsu N, Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003;30(6):450–457. doi: 10.1111/j.1346-8138.2003.tb00415.x
  159. Physical and rehabilitation medicine. The National Guide. Ed. by G.N. Ponomarenko. Moscow: GEOTAR-Media; 2016. 688 p. (In Russ).
  160. Private physiotherapy: A textbook. Ed. by G.N. Ponomarenko. Moscow: Meditsina; 2005. 744 p. (In Russ).
  161. Patrizi A, Raone B, Ravaioli GM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;(8):511–520. doi: 10.2147/CCID.S87987
  162. Dogra S, Mahajan R. Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol Venereol Leprol. 2015;81(1):10–15. doi: 10.4103/0378-6323.148557
  163. Kubanova AA, Samsonov VA, Volnukhin VA, et al. Therapy of patients with psoriasis, atopic dermatitis and vitiligo with narrow-band medium-wave ultraviolet radiation with a wavelength of 311 nm. Medical technology No. FS-2006/250 of August 15, 2006. Bulletin of Dermatology and Venereology. 2008;(3):17–20. (In Russ).
  164. Thompson KG, Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy. Dermatol Clin. 2020;38(1):25–35. doi: 10.1016/j.det.2019.08.003
  165. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293.
  166. Paller AS, Bansal A, Simpson EL, et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–131.
  167. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.
  168. Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020;182(1):85–96.
  169. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
  170. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1
  171. De Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156
  172. Thaçi D, L Simpson E, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi: 10.1016/j.jdermsci.2019.02.002
  173. Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2020;31(6):606–614. doi: 10.1080/09546634.2019.1612836
  174. Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165. doi: 10.1007/s40257-017-0324-7
  175. Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198. doi: 10.1016/j.jdermsci.2018.01.016
  176. Czech W, Brautigam M, Weidinger G, Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000;42(4):653–659.
  177. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52–58. doi: 10.1046/j.1365-2133.2000.03241.x
  178. Granlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol. 2001;81(1):22–27. doi: 10.1080/00015550120235
  179. Zurbriggen B, Wuthrich B, Cachelin AB, et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology. 1999;198(1):56–60. doi: 10.1159/000018065
  180. Hijnen DJ, Ten Berge O, Timmer-de Mik L, et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol. 2007;21(1):85–89. doi: 10.1111/j.1468-3083.2006.01877.x
  181. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619. doi: 10.1111/j.1468-3083.2006.02023.x
  182. Amor KT, Ryan K, Menter A. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol. 2010;63(6):925–946. quiz 947-948. doi: 10.1016/j.jaad.2010.02.063
  183. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi: 10.1111/jdv.14888
  184. Shamov BA. Atopic dermatitis: clinical manifestations and treatment. Diary of the Kazan Medical School. 2014;(1):63–65. (In Russ).
  185. Jung MY, Chung JY, Lee HY, et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015;27(4):398–403. doi: 10.5021/ad.2015.27.4.398
  186. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol. 2003;4(9):641–654. doi: 10.2165/00128071-200304090-00006
  187. Masyukova SA, Gladko EV, Tarasenko GN, et al. Fusidic acid in the treatment of pyodermatitis and allergodermatoses complicated by bacterial infection. Bulletin of Dermatology and Venereology. 2007;(6):54–57. (In Russ).
  188. Dvoryankova EV, Korsunskaya IM, Zakharova AB, Zhukovsky RO. Atopic dermatitis complicated by secondary infection: approaches to therapy. Effective Pharmacotherapy. 2011;(26):74–76. (In Russ).
  189. Larkova IA. Effective therapy of atopic dermatitis in children complicated by secondary infection. Medical Advice. 2016;(1):162–167. (In Russ). doi: 10.21518/2079-701X-2016-1-162-167
  190. Matushevskaya EV, Svirshchevskaya EV. Atopic dermatitis in the practice of a dermatovenerologist: a rational choice of therapy. Russian Medical Journal. 2013;21(8):410–412. (In Russ).
  191. Gong JQ, Lin L, Lin T, et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155(4):680–687. doi: 10.1111/j.1365-2133.2006.07410.x
  192. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol. 1988;119(2):189–198. doi: 10.1111/j.1365-2133.1988.tb03201.x
  193. Albanova V. External treatment of atopic dermatitis. Doctor. 2006;(2):76–78.
  194. Batyrshina SV, Khaertdinova LA. The concept of local therapy of patients with atopic dermatitis. Practical Medicine. 2009;35(3):41–45.
  195. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol. 1976;95(3):323–328. doi: 10.1111/j.1365-2133.1976.tb07021.x
  196. Schuttelaar ML, Coenraads PJ. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2008;22(9):1076–1082. doi: 10.1111/j.1468-3083.2008.02716.x
  197. Vasenova VYu, Butov YuS. The use of Polcortolone TS for the treatment of itchy dermatoses complicated by secondary infection. Russian Medical Journal. 2013;21(22):1096–1098. (In Russ).
  198. Skripkin YuK, Khamaganova IV. Experience of using oxycort and polcortolon TS aerosols in the treatment of allergic dermatoses complicated by pyoderma. Bulletin of Dermatology and Venereology. 2004;(1):42–43. (In Russ).
  199. Ramsay C, Savoie J, Gilbert M, et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol. 1996;7(Suppl. 1):S15–22. doi: 10.1016/0926-9959(96)00032-3
  200. Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica. 1985;4(1):126–131.
  201. Tarasova MV, Marina TV, Sorokina EA, et al. The expediency of using combined topical glucocorticosteroids in the complex therapy of atopic dermatitis. Health and Education in the XXI century. 2008;10(3):383. (In Russ).
  202. Kubanova AA, Proshutinskaya DV, Tekucheva LV, Avdienko IN. Integral approach to external therapy of patients with atopic dermatitis. Bulletin of Dermatology and Venereology. 2010;(1):20–26. (In Russ).
  203. Nenasheva NM. Features of local (external) therapy of atopic dermatitis complicated by infection. RMJ. 2015;23(19):1159–1165. (In Russ).
  204. Kungurov NV, Keniksfest YuV, Kohan MM, et al. Combined external therapy of complicated dermatoses. Clinical Dermatology and Venereology. 2005;(2):33–37. (In Russ).
  205. Niebuhr M, Mai U, Kapp A, Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Exp Dermatol. 2008;17(11):953–957. doi: 10.1111/j.1600-0625.2008.00734.x
  206. Boguniewicz M, Sampson H, Leung S, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis. J Allergy Clin Immunol. 2001;108(4):651–652. doi: 10.1067/mai.2001.118598
  207. Treneva MS, Pampura AN. Strategy of choosing antibacterial drugs in children with microbial infection of atopic dermatitis. Practical Medicine. 2011;(3):136–139. (In Russ).
  208. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4–13. quiz 14-15. doi: 10.1016/j.jaci.2009.11.027
  209. Tognetti L, Martinelli C, Berti S, et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012;26(8):931–941. doi: 10.1111/j.1468-3083.2011.04416.x
  210. Petry V, Bessa GR, Poziomczyck CS, et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012;87(5):729–734. doi: 10.1590/s0365-05962012000500010
  211. Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012;(96):89–95. doi: 10.1159/000331892
  212. Niimura M, Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med.1988;85(2A):49–52.
  213. Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006;118(6):1292–1298. doi: 10.1016/j.jaci.2006.07.054
  214. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep. 2011;11(4):277–283. doi: 10.1007/s11882-011-0194-7
  215. Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110–117. doi: 10.1016/j.jaci.2013.02.044
  216. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol. 1982;107(5):597–602. doi: 10.1111/j.1365-2133.1982.tb00412.x
  217. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy. 1992;22(4):440–446. doi: 10.1111/j.1365-2222.1992.tb00145.x
  218. Zachariae H, Cramers M, Herlin T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1985;(114):48–54. doi: 10.2340/000155551144854
  219. Yelisyutina OG, Fedenko ES. The place of specific immunotherapy in the treatment of patients with atopic dermatitis complicated by recurrent pyoderma. Physiology and Pathology of the Immune System. 2006;(8):15. (In Russ).
  220. Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012;130(4):925– 931e4. doi: 10.1016/j.jaci.2012.08.004
  221. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164–170. doi: 10.1016/j.jaci.2007.04.008
  222. Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014;53(5):650–655. doi: 10.1111/ijd.12302
  223. Liu L, Guo D, Liang Q, et al. The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy. 2015;45(4):815–822. doi: 10.1111/cea.12417
  224. Roduit C, Frei R, Loss G, et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol. 2012;130(1):130–136e5. doi: 10.1016/j.jaci.2012.02.043
  225. Perkin MR, Logan K, Tseng A, et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med. 2016;374(18):1733–1743. doi: 10.1056/NEJMoa1514210
  226. Prell C, Koletzko B. Breastfeeding and complementary feeding. Dtsch Arztebl Int. 2016;113(25):435–444. doi: 10.3238/arztebl.2016.0435
  227. Vandenplas Y, Al-Hussaini B, Al-Mannaei K, et al. Prevention of allergic sensitization and treatment of cow’s milk protein allergy in early life: the middle-east step-down consensus. Nutrients. 2019;11(7):1444. doi: 10.3390/nu11071444
  228. Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Exp Rev Clin Immunol. 2012;8(1):17–19. doi: 10.1586/eci.11.74
  229. Cuello-Garcia CA, Brozek JL, Fiocchi A, et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2015;136(4):952–961. doi: 10.1016/j.jaci.2015.04.031
  230. Panduru М, Panduru NM, Sălăvăstru CM, Tiplica GS. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol. 2015;29(2):232–242. doi: 10.1111/jdv.12496
  231. Muraro A, Halken S, Arshad SH, et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy. 2014;69(5):590–601. doi: 10.1111/all.12398
  232. Kantor R, Kim A, Thyssen JP, Silverberg JI. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(6):1119–1125e1. doi: 10.1016/j.jaad.2016.07.017
  233. Kathuria P, Silverberg JI. Association of pollution and climate with atopic eczema in US children. Pediatr Allergy Immunol. 2016;27(5):478–485. doi: 10.1111/pai.12543
  234. Morgenstern V, Zutavern A, Cyrys J, et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am J Respir Crit Care Med. 2008;177(12):1331–1337. doi: 10.1164/rccm.200701-036OC
  235. Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18(1):64–73. doi: 10.1038/ni.3614
  236. Ricci G, Bendandi B, Aiazzi R, et al. Three years of Italian experience of an educational program for parents of young children affected by atopic dermatitis: improving knowledge produces lower anxiety levels in parents of children with atopic dermatitis. Pediatr Dermatol. 2009;26(1):1–5. doi: 10.1111/j.1525-1470.2008.00813.x
  237. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332(7547):933–938. doi: 10.1136/bmj.332.7547.933
  238. Lambert J, Bostoen J, Geusens B, et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. Arch Dermatol Res. 2011;303(1):57–63. doi: 10.1007/s00403-010-1082-z
  239. Kupfer J, Gieler U, Diepgen TL, et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J Psychosom Res. 2010;68(4):353–358. doi: 10.1016/j.jpsychores.2009.04.014
  240. Staab D, von Rueden U, Kehrt R, et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002;13(2):84–90. doi: 10.1034/j.1399-3038.2002.01005.x
  241. Kiriyama T, Sugiura H, Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis. J Dermatol. 2003;30(10):708–712. doi: 10.1111/j.1346-8138.2003.tb00463.x
  242. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006;19(6):296–302. doi: 10.1159/000094670
  243. Simpson E, Trookman NS, Rizer RL, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012;29(5):590–597. doi: 10.1111/j.1525-1470.2012.01809.x
  244. Hon KL, Leung TF, Wong Y, et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005;30(4):351–354. doi: 10.1111/j.1365-2230.2005.01748.x
  245. Wollenberg A, Vogel S, Renner ED. Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases. (In German). Hautarzt. 2010;61(11):985–993. doi: 10.1007/s00105-010-2019-3
  246. Bath-Hextall F, Delamere F, Williams H. Dietary exclusions for improving established atopic eczema in adults and children systematic review. Allergy. 2009;64(2):258–264. doi: 10.1111/j.1398-9995.2008.01917.x
  247. National calendar of preventive vaccinations. Appendix No. 1 to the order of the Ministry of Health of the Russian Federation of March 21, 2014. No. 125n. (In Russ). Available from: https://base.garant.ru/70647158/53f89421bbdaf741eb2d1ecc4ddb4c33/. Accessed: December 15, 2020.
  248. Allergology and immunology: national guidelines. Ed. by R.M. Khaitov, N.I. Ilyina. Moscow: GEOTAR-Media; 2009. 634 p. (In Russ).
  249. Campana R, Dzoro S, Mittermann I, et al. Molecular aspects of allergens in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2017;17(4):269–277. doi: 10.1097/ACI.0000000000000378
  250. Cartledge N, Chan S. Atopic Dermatitis and food allergy: a paediatric approach. Curr Pediatr Rev. 2018;14(3):171–179. doi: 10.2174/1573396314666180613083616
  251. Darsow U, Laifaoui J, Kerschenlohr K, et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: A European multicenter study. Allergy. 2004;59(12):1318–1325. doi: 10.1111/j.1398-9995.2004.00556.x
  252. Tamagawa-Mineoka R, Katoh N. Atopic dermatitis: identification and management of complicating factors. Int J Mol Sci. 2020;21(8):2671. doi: 10.3390/ijms21082671
  253. Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96–103.e9. doi: 10.1016/j.jaci.2015.04.015
  254. Caut C, Leach M, Steel A. Dietary guideline adherence during preconception and pregnancy: A systematic review. Matern Child Nutr. 2020;16(2):e12916. doi: 10.1111/mcn.12916
  255. Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020;69(2):204–214. doi: 10.1016/j.alit.2019.08.013
  256. Fedenko E, Elisyutina O, Shtyrbul O, et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016;27(6):645–649. doi: 10.1111/pai.12572
  257. Alexander DD, Cabana MD. Partially hydrolyzed 100% whey protein infant formula and reduced risk of atopic dermatitis: a meta-analysis. J Pediatr Gastroenterol Nutr. 2010;50(4):422–430.
  258. Niggemann B, Reibel S, Wahn U. The atopy patch test (APT)–a useful tool for the diagnosis of food allergy in children with atopic dermatitis. Allergy. 2000;55(3):281–285.
  259. Sampson HA, Albergo R. Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 1984;74(1):26–33.
  260. Roehr CC, Reibel S, Ziegert M, et al. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):548–553. doi: 10.1067/mai.2001.112849

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (693KB)
Indexing metadata
3. Fig. 2

Download (333KB)
Indexing metadata
4. Fig. 3

Download (261KB)
Indexing metadata

Copyright (c) 2021 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies